Scrip

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

Key Points: 
  • The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.
  • The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare.
  • It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.
  • Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI's clinical studies.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

Retrieved on: 
Friday, November 17, 2023

NATICK, Mass. and LONDON, Nov. 17, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards. This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe. AffyImmune topped the list of six finalists deemed to be pioneering new approaches in the treatment of cancer that have shown proof of concept in early clinical trials and have candidates moving forward in the development pathway.

Key Points: 
  • and LONDON, Nov. 17, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards .
  • This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe.
  • "We're thrilled to receive the award, especially in an impressive group of finalists this year; this award is a recognition of the hard work of the AffyImmune team," Chief Operating Officer Matt Britz said.
  • We truly appreciate the confirmation from Scrip and the exposure for our candidate which we believe could greatly improve patient outcomes."

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

Plan Ahead for Employee Gifts! Show Gratitude with Turkey, Ham or Grocery Gift Certificates

Retrieved on: 
Monday, November 1, 2021

gThankYou creates custom Certificates of Gratitude(TM) that are given as employee and customer gifts, good for popular and practical food items such as a Thanksgiving turkey , Christmas ham or groceries .

Key Points: 
  • gThankYou creates custom Certificates of Gratitude(TM) that are given as employee and customer gifts, good for popular and practical food items such as a Thanksgiving turkey , Christmas ham or groceries .
  • The Gift Certificates are redeemable for any brand at major U.S. grocery stores.
  • Nothing says "Thank You" like the gift of a Thanksgiving turkey it's a uniquely American gift that's an iconic symbol of gratitude.
  • Based in Madison, Wisconsin, gThankYou is the leader in Turkey and Turkey Or Ham Gift Certificates for Thanksgiving and holiday employee gifts.

DGAP-News: ENCAVIS AG: Major part of Encavis' shareholders (42.9%) prefer new Encavis shares to cash dividend

Retrieved on: 
Monday, June 28, 2021

A total of 814,031 new shares will therefore be issued and a cash dividend of 26,877,572.92 euros distributed to shareholders.

Key Points: 
  • A total of 814,031 new shares will therefore be issued and a cash dividend of 26,877,572.92 euros distributed to shareholders.
  • After the registration in the Commercial Register, 139,251,265 Encavis AG shares will be listed on the stock exchange.
  • The scrip dividend offered for the past fiscal year 2020 already represented the eight time in a row that the company has offered this option.
  • Encavis AG's environmental, social and governance performance has been awarded by two of the world's leading ESG rating agencies.

DGAP-News: BP p.l.c.: Q1 2021 Payments of dividends in sterling

Retrieved on: 
Tuesday, June 8, 2021

announced that the interim dividend for the first quarter 2021 would be US$0.0525 per ordinary share (US$0.315 per ADS).

Key Points: 
  • announced that the interim dividend for the first quarter 2021 would be US$0.0525 per ordinary share (US$0.315 per ADS).
  • This interim dividend is to be paid on 18 June 2021 to shareholders on the share register on 7 May 2021.
  • The dividend is payable in cash in sterling to holders of ordinary shares and in US dollars to holders of ADSs.
  • The board has decided not to offer a scrip dividend alternative in respect of the first quarter 2021 dividend.

DGAP-News: Baader Bank AG: Annual General Meeting to be held virtually again in 2021; scrip dividend for shareholders

Retrieved on: 
Thursday, May 20, 2021

b'Baader Bank AG: Annual General Meeting to be held virtually again in 2021; scrip dividend for shareholders\nThe issuer is solely responsible for the content of this announcement.\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.\nAnnual General Meeting to be held virtually again in 2021; scrip dividend for shareholders\nBaader Bank will once again hold its Annual General Meeting virtually this year.

Key Points: 
  • b'Baader Bank AG: Annual General Meeting to be held virtually again in 2021; scrip dividend for shareholders\nThe issuer is solely responsible for the content of this announcement.\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.\nAnnual General Meeting to be held virtually again in 2021; scrip dividend for shareholders\nBaader Bank will once again hold its Annual General Meeting virtually this year.
  • A video of the entire Annual General Meeting will be made available on the homepage of the Baader Bank website at 10.00 am on 1 July 2021 via a password-protected Internet service.
  • Shareholders who wish to participate in the virtual shareholders\' meeting must have registered by no later than the stipulated deadline.
  • The shares offered are Baader Bank\'s own shares and new Baader Bank shares from a subscription rights capital increase.